Serological immune response to cancer testis antigens in patients with pancreatic cancer

Abstract

Serological screening approaches have allowed for the identification of a large number of potentially relevant tumor antigens in cancer patients. Within this group, cancer testis antigens represent promising targets for cancer immunotherapy, since they are widely expressed in a variety of human cancer entities. In pancreatic cancer, however, there are only few data available about the expression pattern and serological response to cancer testis antigens and other serological‐defined tumor antigens. Therefore, we investigated the IgG antibody response against 11 cancer testis antigens (SCP‐1, GAGE, LAGE‐1a,‐1b, CT‐7, NY‐ESO‐1, SSX‐1‐5) recombinantly expressed on yeast surface (RAYS) in patients with pancreatic cancer (n = 96), chronic pancreatitis (n = 18) and healthy donors (n = 48). We found in 14% of all patients antibody responses to SCP‐1, but not to other cancer testis antigens (GAGE, LAGE‐1a,‐1b, CT‐7, NY‐ESO‐1, SSX‐1‐5). Antibody response correlated with the expression of SCP‐1 in the primary tumor of the respective patient as shown by RT‐PCR, immunohistochemistry and Western blot. In contrast, no serological response to cancer testis antigens was observed in healthy donors. The humoral immune response against SCP‐1 was associated with the size of tumor, but not with other clinico‐pathological parameters such as histology, stage, presence of lymph node metastases, grading, age, gender or gemcitabine treatment. In conclusion, antibody response to cancer testis antigen SCP‐1 is found in a proportion of pancreatic carcinoma patients. These results indicate that identification of additional tumor antigens by serological screening of tumor cDNA expression libraries by RAYS is a promising goal in pancreatic cancer.